The Lessebo Effect in Disease Modification Trials in Parkinson's Disease
Open Access
- 24 April 2023
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 38 (7) , 1346-1350
Abstract
Background: The impact of expectation of benefit on outcomes is well established in Parkinson's disease (PD). A reduction of a treatment effect due to a perceived placebo allocation (lessebo effect) in randomized controlled trials (RCTs) was documented for symptomatic treatments.Objectives: To evaluate the lessebo effect in disease modification RCTs (DMT) in PD.Methods: Subject‐level meta‐analyses of active treatment arms of DMT (n = 1149 subjects): FS‐1, FS‐TOO (probability of placebo allocation/P(placebo) = 0.33) and DATATOP, PRECEPT, QE2 (P(placebo) = 0.25). We tested the association between P(placebo) and time to dopaminergic treatment initiation using a marginal Cox proportional hazards model.Results: The adjusted hazard ratio (P(placebo) = 0.25 vs. 0.33) for initiation of dopaminergic treatment was 1.15 (95% CI: 0.92–1.43).Conclusions: We did not observe the lessebo effect in DMT. The necessary use of a placebo (and no active comparator) is a limitation. The prospective measurement of expectation of benefit could help to evaluate the many impacts of placebo use. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.Keywords
This publication has 17 references indexed in Scilit:
- Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohortsMovement Disorders, 2011
- Does Inclusion of a Placebo Arm Influence Response to Active Antidepressant Treatment in Randomized Controlled Trials?The Journal of Clinical Psychiatry, 2010
- Patients' preferences within randomised trials: systematic review and patient level meta-analysisBMJ, 2008
- A Pilot Clinical Trial of Creatine and Minocycline in Early Parkinson DiseaseClinical Neuropharmacology, 2008
- Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventionsMovement Disorders, 2008
- Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson diseaseNeurology, 2007
- A randomized clinical trial of coenzyme Q 10 and GPI-1485 in early Parkinson diseaseNeurology, 2007
- Impact of placebo assignment in clinical trials of Parkinson's diseaseMovement Disorders, 2003
- Cox-Type Regression Analysis for Large Numbers of Small Groups of Correlated Failure Time Observations1992
- DATATOP: A Multicenter Controlled Clinical Trial in Early Parkinson's DiseaseArchives of Neurology, 1989